Cancer remains the leading disease-related cause of death in dogs, affecting approximately one in four pets and accounting for nearly 50% of deaths in dogs over age 10. As veterinary medicine advances, so too does our ability to diagnose, characterize, and monitor canine cancers with the same molecular precision available in human oncology. Gene expression profiling through quantitative real-time PCR (qPCR) has emerged as a powerful diagnostic tool that veterinary oncologists and general practitioners can leverage to provide better outcomes for their canine patients.

Unlike traditional diagnostic methods that rely primarily on histopathology and imaging, qPCR gene expression analysis offers quantitative, molecular-level insights into tumor biology. This technology allows veterinarians to identify prognostic markers, classify cancer subtypes more accurately, monitor treatment response, and detect minimal residual disease—capabilities that translate directly into improved clinical decision-making and better conversations with pet owners about prognosis and treatment options.

At ARQ Genetics, we’ve adapted our PhD-level expertise in gene expression analysis to serve the veterinary oncology community. Working without the regulatory constraints of CLIA or GLP requirements that burden human diagnostic testing, we can offer veterinarians fast, affordable, and expertly interpreted gene expression profiling specifically designed for canine cancer cases. Whether you’re a board-certified veterinary oncologist managing complex cases or a general practitioner seeking molecular insights to guide referral decisions, qPCR analysis provides actionable data that enhances patient care.

This comprehensive guide explores how qPCR gene expression analysis applies to canine cancer diagnostics, which cancers and genes are most clinically relevant, and how veterinary professionals can integrate this powerful tool into their practice.

Understanding Gene Expression Profiling in Canine Oncology

What is qPCR Gene Expression Analysis?

Quantitative real-time PCR (qPCR) measures the expression levels of specific genes by quantifying messenger RNA (mRNA) in tissue samples. Unlike genomic DNA testing that identifies mutations, gene expression analysis reveals which genes are actively “turned on” or “turned off” in tumor tissue compared to normal tissue or compared across different tumor samples.

This distinction is crucial in oncology because cancer isn’t just about mutations—it’s about dysregulated gene expression. A tumor might have normal DNA sequences for a particular gene, but that gene could be massively overexpressed or completely silenced, driving cancer progression. qPCR captures these expression changes with exceptional sensitivity and quantitative precision.

Why Gene Expression Matters in Canine Cancer

The same molecular principles that govern human cancer biology apply to canine cancers, making dogs not only patients deserving of advanced diagnostics but also valuable models for understanding cancer in both species. Gene expression patterns in canine tumors can reveal:

Prognostic Information: Certain gene expression signatures correlate strongly with survival outcomes, helping predict whether a dog is likely to respond well to treatment or faces a more aggressive disease course.

Cancer Subtype Classification: Many canine cancers encompass multiple subtypes with different biological behaviors. Gene expression profiling can distinguish between these subtypes even when they appear similar under the microscope, enabling more precise treatment selection.

Treatment Response Prediction: Expression levels of specific genes can indicate whether a tumor is likely to respond to particular chemotherapy agents, targeted therapies, or immunotherapies.

Minimal Residual Disease Detection: After treatment, even when tumors appear to be in remission on imaging, qPCR can detect low levels of cancer-specific gene expression that may indicate residual disease requiring continued monitoring or treatment adjustment.

The Clinical Advantage of qPCR

Compared to other molecular profiling methods, qPCR offers veterinary practitioners several practical advantages:

Cost-Effectiveness: qPCR analyzes specific genes of known clinical relevance rather than surveying the entire genome or transcriptome. This targeted approach dramatically reduces cost while providing the specific information needed for clinical decisions.

Fast Turnaround: While next-generation sequencing (NGS) often requires 2-3 weeks for results, qPCR can deliver data in 5-7 business days—a timeline that better matches the urgency of clinical decision-making in veterinary oncology.

Quantitative Precision: qPCR provides numerical fold-change values rather than relative comparisons, allowing for objective assessment of gene expression levels and more standardized interpretation across different samples and time points.

Flexible Sample Types: qPCR works well with FFPE (formalin-fixed paraffin-embedded) tissue, fresh frozen samples, and even fine needle aspirates—the sample types routinely collected in veterinary practice.

Validation in Veterinary Literature: Unlike some human-focused technologies that haven’t been validated in dogs, qPCR-based gene expression studies have been extensively published in veterinary oncology journals, providing evidence-based confidence in the approach.

Common Canine Cancers and Clinically Relevant Genes

Gene expression profiling has been validated across multiple canine cancer types, with specific genes emerging as clinically useful markers for prognosis, classification, or treatment guidance.

Canine Lymphoma

Lymphoma is the most common hematologic malignancy in dogs, accounting for approximately 7-24% of all canine cancers. While traditionally classified by anatomical location and histological grade, molecular profiling has revealed important biological subtypes that behave differently and may benefit from different treatment approaches.

Key Genes and Clinical Utility:

BCL2 (B-cell lymphoma 2): Overexpression of BCL2, an anti-apoptotic gene, is associated with resistance to chemotherapy-induced cell death. Dogs with lymphomas showing high BCL2 expression may benefit from treatment protocols that include BCL2 inhibitors or alternative chemotherapy regimens less dependent on apoptosis induction.

MYC (Myelocytomatosis oncogene): MYC overexpression drives aggressive cell proliferation and is associated with shorter remission duration and overall survival. Identifying MYC-high lymphomas can inform pet owners about prognosis and guide decisions about treatment intensity.

TP53 (Tumor protein p53): While TP53 mutations are typically assessed at the genomic level, TP53 expression levels also provide prognostic information. Loss of TP53 expression correlates with more aggressive disease and poorer treatment response.

KI67 (Marker of proliferation): Though technically a proliferation marker rather than a driver gene, KI67 expression quantified by qPCR provides an objective measure of tumor growth rate that complements histological grading.

Clinical Application: A veterinary oncologist treating a dog with multicentric B-cell lymphoma might use gene expression profiling to identify cases with high BCL2 and MYC expression, indicating more aggressive disease that could benefit from intensified induction therapy or early consideration of rescue protocols when first-line treatment fails.

Osteosarcoma

Canine osteosarcoma is an aggressive bone cancer with high metastatic potential, primarily affecting large and giant breed dogs. Despite aggressive treatment including amputation and chemotherapy, median survival remains around 12 months due to micrometastatic disease present at diagnosis. Gene expression profiling offers promise for identifying which patients face highest metastatic risk and might benefit from more aggressive or novel therapies.

Key Genes and Clinical Utility:

ANKRD17 (Ankyrin repeat domain 17): Upregulation of ANKRD17 has been associated with poor survival in canine osteosarcoma, potentially reflecting dysregulation of cell cycle control pathways.

MGST1 (Microsomal glutathione S-transferase 1): Overexpression of MGST1, involved in drug metabolism and detoxification, may contribute to chemotherapy resistance. Dogs with high MGST1 expression might benefit from alternative drug protocols or dose intensification strategies.

NCOR1 (Nuclear receptor corepressor 1): NCOR1 expression levels correlate with metastatic potential and overall survival. Low NCOR1 expression indicates higher metastatic risk.

MRPS31 (Mitochondrial ribosomal protein S31): Elevated expression is associated with poor outcomes, possibly reflecting increased metabolic activity supporting rapid tumor growth.

Ezrin (EZR): High ezrin protein expression (which correlates with mRNA levels) has been validated as a negative prognostic factor in multiple studies. Ezrin facilitates cellular motility and metastasis, making it a rational therapeutic target as well as a prognostic marker.

Clinical Application: For a dog diagnosed with appendicular osteosarcoma undergoing amputation and chemotherapy, gene expression profiling at the time of surgery could stratify metastatic risk. Dogs with high-risk gene expression profiles might be candidates for metronomic chemotherapy, immunotherapy trials, or more intensive surveillance protocols, while lower-risk patients might follow standard protocols with confidence.

Mast Cell Tumors

Mast cell tumors (MCTs) are among the most common skin cancers in dogs, with behavior ranging from benign to highly malignant. Histological grading (Patnaik or Kiupel systems) provides some prognostic information, but molecular markers offer additional precision for predicting behavior and guiding treatment decisions.

Key Genes and Clinical Utility:

KIT (KIT proto-oncogene receptor tyrosine kinase): KIT mutations and overexpression are hallmarks of canine MCT. While mutations require DNA sequencing, KIT mRNA overexpression detected by qPCR can help identify cases likely to respond to tyrosine kinase inhibitors like toceranib phosphate or masitinib.

TP53: As in other cancers, TP53 expression levels correlate with prognosis. Loss of TP53 expression indicates higher-grade disease with greater metastatic potential.

VEGF (Vascular endothelial growth factor): High VEGF expression promotes angiogenesis and tumor growth. VEGF levels can help identify tumors with high metastatic potential and may guide use of anti-angiogenic therapies.

Tryptase and Chymase: These mast cell-specific proteases serve as markers of mast cell differentiation. Expression patterns can help confirm mast cell origin in ambiguous cases and may correlate with degranulation behavior.

Clinical Application: A general practitioner removing a grade 2 MCT might submit tissue for gene expression analysis to determine if the tumor shows high KIT and VEGF expression. This information could guide recommendations for adjuvant therapy (tyrosine kinase inhibitor treatment) or influence decisions about surgical margins and follow-up intensity.

Hemangiosarcoma

Canine hemangiosarcoma is an aggressive endothelial cancer with poor prognosis, commonly affecting the spleen, liver, and heart. Metastasis is typically present at diagnosis even when not visible on imaging. Gene expression profiling may help identify the small subset of dogs with more favorable biology and guide development of targeted therapies.

Key Genes and Clinical Utility:

VEGF (Vascular endothelial growth factor): Hemangiosarcoma is fundamentally a disease of aberrant blood vessel formation, making VEGF a central player. VEGF expression levels might predict response to anti-angiogenic therapies.

PECAM1/CD31 (Platelet endothelial cell adhesion molecule): As an endothelial marker, CD31 expression confirms tumor origin and may correlate with degree of endothelial differentiation.

Aurora kinases (AURKA, AURKB): These cell cycle regulators are often overexpressed in hemangiosarcoma and represent potential therapeutic targets. Expression profiling could identify cases suitable for aurora kinase inhibitor trials.

PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha): Mutations in the PI3K pathway are common in hemangiosarcoma. While mutations require DNA sequencing, overexpression of PIK3CA and related pathway genes can be detected by qPCR and might predict response to PI3K inhibitors.

Clinical Application: After splenectomy for hemangiosarcoma, a veterinary oncologist might use gene expression profiling to identify cases with specific pathway dysregulation (e.g., high PI3K pathway activation) that could be enrolled in clinical trials of targeted therapies, or to stratify prognosis for discussions with pet owners about treatment intensity.

Mammary Carcinomas

Canine mammary tumors are common in intact female dogs, with approximately 50% being malignant. Like human breast cancer, canine mammary carcinomas show molecular heterogeneity that affects prognosis and treatment response.

Key Genes and Clinical Utility:

Estrogen Receptor (ESR1) and Progesterone Receptor (PGR): Hormone receptor expression predicts whether tumors might respond to hormonal therapies (ovariohysterectomy, selective estrogen receptor modulators). ER/PR-positive tumors generally have better prognosis.

HER2/ERBB2 (Human epidermal growth factor receptor 2): HER2 overexpression identifies an aggressive subtype of mammary carcinoma. While HER2-targeted therapies (trastuzumab) are primarily human drugs, HER2 status provides important prognostic information and may guide enrollment in veterinary trials of HER2-targeted agents.

COL1A1 (Collagen type I alpha 1): Overexpression in cancer-associated stroma correlates with aggressive tumor behavior, reflecting the tumor’s ability to remodel surrounding tissue to support invasion and metastasis.

FAP (Fibroblast activation protein): FAP expression in tumor-associated fibroblasts indicates activated stroma that facilitates tumor progression. High FAP expression is associated with poorer prognosis.

CXCL12 (C-X-C motif chemokine ligand 12): Downregulation of CXCL12 in tumor stroma is associated with more aggressive disease, possibly reflecting loss of normal stromal architecture.

Clinical Application: A veterinarian removing a canine mammary carcinoma could submit tissue for receptor profiling (ER, PR, HER2) to guide recommendations about ovariohysterectomy timing and to provide prognostic information that helps pet owners make informed decisions about chemotherapy or more aggressive surveillance.

The Veterinary Advantage: No CLIA or GLP Barriers

One of the most significant advantages of qPCR gene expression analysis for veterinary diagnostics is the absence of regulatory barriers that constrain human diagnostic testing.

Understanding the Regulatory Landscape

CLIA (Clinical Laboratory Improvement Amendments): In human medicine, any laboratory performing diagnostic testing on human samples must obtain CLIA certification, a complex and expensive regulatory framework involving facility standards, proficiency testing, quality control documentation, and regular inspections.

GLP (Good Laboratory Practices): For human drug development and certain diagnostic applications, GLP compliance requires extensive documentation, standard operating procedures, quality assurance oversight, and audit trails that significantly increase operational costs and turnaround times.

Veterinary Exception: Animal diagnostic testing is not subject to CLIA requirements, and most veterinary diagnostics do not require GLP compliance. This regulatory flexibility allows veterinary diagnostic providers to operate with lower overhead while maintaining scientific rigor.

What This Means for Veterinarians

Lower Costs: Without CLIA overhead (facility requirements, additional personnel, extensive QC documentation), we can offer research-grade qPCR analysis at veterinary-accessible pricing that’s significantly more affordable than equivalent human diagnostic testing.

Faster Turnaround: Streamlined workflows without extensive regulatory documentation requirements mean we can deliver results in 5-7 business days rather than the 2-3 weeks common in CLIA-certified human diagnostic labs.

Greater Flexibility: We can design custom gene panels specifically for your cases without navigating regulatory approval processes. If you’re treating an unusual cancer or want to profile a specific set of genes based on recent literature, we can create that panel quickly and efficiently.

Direct Scientist Consultation: Our PhD-level scientists work directly with veterinarians to interpret results and provide guidance without layers of regulatory compliance personnel acting as intermediaries. This direct access means better communication and more clinically relevant insights.

Research-Grade Quality Without Research Delays: You get the same scientific expertise and analytical rigor that serves academic researchers, but with the responsiveness and practical focus that clinical veterinary practice demands.

Maintaining Scientific Rigor

The absence of CLIA requirements doesn’t mean lower quality—it means appropriate quality for the application. Our qPCR services for veterinary oncology include:

  • PhD-level scientists with years of gene expression expertise
  • Validated primer/probe sets based on published veterinary literature
  • Proper controls including no-RT controls and reference gene normalization
  • Comprehensive QC including RNA integrity assessment
  • Statistical analysis and fold-change calculations
  • Complete data transparency (raw Ct values, all replicates, QC metrics)
  • Interpretation guidance from scientists who understand comparative oncology

Comparing qPCR to Other Diagnostic Modalities

Veterinarians have several molecular and cellular diagnostic options for cancer characterization. Understanding where qPCR fits in the diagnostic toolkit helps maximize its clinical utility.

qPCR vs. Immunohistochemistry (IHC)

Immunohistochemistry detects protein expression in tissue sections using antibodies, providing spatial information about where proteins are expressed within the tumor.

Advantages of qPCR:

  • Quantitative: qPCR provides numerical fold-change values, not subjective scoring (1+, 2+, 3+)
  • Broader Gene Coverage: Can assess dozens of genes in a single panel; IHC typically evaluates one protein per section
  • More Sensitive: Detects expression changes that might not produce enough protein for IHC detection
  • Less Ambiguous: Numerical data is more objective than visual interpretation of staining intensity
  • Works with Degraded Samples: Can succeed with partially degraded FFPE tissue where antibody epitopes might be compromised

When IHC is Preferable:

  • When spatial information matters (which cells express the marker?)
  • For established protein markers with validated antibodies (e.g., HER2, ER)
  • When pathologists need to correlate protein expression with tissue architecture

Complementary Use: Many cases benefit from both—IHC for initial assessment and spatial information, qPCR for quantitative confirmation and broader gene profiling.

qPCR vs. Next-Generation Sequencing (NGS)

Next-generation sequencing can analyze thousands of genes simultaneously, providing comprehensive genomic and transcriptomic information.

Advantages of qPCR:

  • Much More Affordable: qPCR panels cost $500-2,000; NGS costs $3,000-8,000+
  • Faster Turnaround: 5-7 days vs. 2-3 weeks for NGS
  • Targeted and Relevant: Focuses on genes with known clinical utility rather than generating vast datasets requiring bioinformatic expertise to interpret
  • Better for Expression Quantification: qPCR is the gold standard for quantifying specific gene expression levels; NGS provides estimates that often require qPCR validation
  • Lower Input Requirements: Needs less RNA and works with lower-quality RNA than many NGS protocols

When NGS is Preferable:

  • When you don’t know which genes to look for (discovery rather than validation)
  • For identifying mutations, not just expression changes
  • For comprehensive transcriptomic profiling in research contexts
  • When sample and budget constraints aren’t limiting factors

Complementary Use: NGS for initial discovery and broad profiling (often in research settings); qPCR for clinical validation and routine diagnostic use of established gene panels.

qPCR vs. Flow Cytometry/Immunophenotyping

Flow cytometry analyzes surface protein expression on individual cells, particularly useful for hematologic cancers.

Advantages of qPCR:

  • Works on Solid Tissues: Flow cytometry requires viable cells in suspension; qPCR works on any tissue type
  • Gene Expression vs. Surface Proteins: qPCR assesses mRNA levels, capturing regulatory changes before protein translation
  • Stable Samples: FFPE tissue is fine; flow cytometry requires fresh samples processed quickly
  • Broader Gene Panel: Can assess intracellular genes and transcription factors not accessible to flow cytometry

When Flow Cytometry is Preferable:

  • For lymphoma/leukemia immunophenotyping (distinguishing B-cell from T-cell, identifying specific markers)
  • When analyzing mixed cell populations and needing to identify specific cell subsets
  • For functional assays (viability, proliferation, apoptosis)

Complementary Use: Flow cytometry for initial lymphoma diagnosis and classification; qPCR for prognostic marker profiling and monitoring.

Working with ARQ Genetics: Custom Canine Cancer Gene Panels

At ARQ Genetics, we specialize in designing qPCR gene expression panels tailored to the specific needs of veterinary oncology. Unlike commercial diagnostic companies offering one-size-fits-all tests, we work with you to create panels that address your clinical questions.

Custom Panel Design Process

Step 1: Initial Consultation (Free)

Contact us to discuss your case or caseload. Our PhD scientists will:

  • Understand the cancer types you most commonly treat
  • Review relevant veterinary oncology literature for validated genes
  • Discuss your clinical goals (prognosis, treatment selection, monitoring)
  • Recommend genes based on published evidence and clinical utility

Step 2: Panel Design

We create a custom panel that might include:

  • Prognostic markers: Genes that predict survival or treatment response
  • Pathway analysis: Groups of genes representing key cancer pathways (apoptosis, cell cycle, metastasis)
  • Treatment-relevant genes: Markers that guide therapy selection
  • Reference genes: Validated endogenous controls for accurate normalization in canine tissue

We’ll provide you with:

  • Complete gene list with symbols and full names
  • Brief description of each gene’s function and clinical relevance
  • Literature references supporting gene selection
  • Transparent pricing

Step 3: Sample Collection and Submission

We accept multiple sample types commonly available in veterinary practice:

FFPE Tissue Blocks or Slides:

  • Most convenient for retrospective analysis
  • Requires 4-5 unstained slides (10 micron thickness) or tissue scrolls
  • Ships at room temperature
  • RNA extraction optimized for FFPE tissue

Fresh Frozen Tissue:

  • Highest RNA quality
  • Minimum 50mg tissue
  • Snap-frozen and shipped on dry ice
  • Ideal for prospective studies

Fine Needle Aspirates (FNA):

  • Can work with cytology samples in some cases
  • Contact us to discuss specific requirements
  • May require more material than diagnostic cytology

Previously Isolated RNA:

  • If you’ve already extracted RNA: minimum 1μg total RNA
  • Provide quality metrics (260/280 ratio, RIN score if available)

We provide detailed sample submission instructions and prepaid shipping labels.

Step 4: RNA Extraction and Quality Control

Upon sample receipt, we:

  • Extract total RNA using methods optimized for your sample type
  • Assess RNA concentration (NanoDrop spectrophotometry)
  • Evaluate RNA integrity (Agilent Bioanalyzer) to ensure sample quality
  • Contact you immediately if samples don’t meet quality thresholds

Quality control is crucial—poor RNA quality produces unreliable results. If we identify quality issues, we’ll work with you to troubleshoot or obtain better samples rather than proceeding with questionable data.

Step 5: qPCR Analysis

We perform quantitative real-time PCR using:

  • High-throughput instrumentation: 7900 HT and CFX-384 real-time PCR systems
  • Validated assays: TaqMan or SYBR Green assays depending on gene and application
  • Proper controls: No-RT controls (rule out genomic DNA), no-template controls, positive controls
  • Technical replication: All samples run in triplicate to ensure reproducibility
  • Reference gene normalization: Multiple validated reference genes for accurate quantification

Step 6: Data Analysis and Interpretation

We provide comprehensive analysis including:

  • ΔΔCt analysis: Fold-change calculations normalized to reference genes
  • Statistical analysis: Appropriate statistical tests comparing tumor to normal tissue or comparing across groups
  • Quality metrics: Amplification efficiency, dissociation curves (SYBR Green), Ct value distributions
  • Publication-ready graphs: Bar graphs, heat maps, volcano plots as appropriate

Step 7: Results Delivery and Consultation

Within 5-7 business days of sample receipt, you receive:

  • Complete PDF report with analysis and interpretation
  • Excel file with raw Ct values, normalized data, and statistical results
  • Publication-quality figures
  • Written interpretation of findings in clinical context

Included with every panel: PhD scientist consultation to discuss results, answer questions, and provide guidance on clinical interpretation. We’re not just a lab service—we’re scientific partners helping you translate molecular data into better patient care.

Sample Case: Custom Lymphoma Panel

Clinical Scenario: A veterinary oncologist treats 20-30 canine lymphoma cases per year and wants to better stratify prognosis at diagnosis to guide intensity of treatment recommendations and help pet owners make informed decisions.

Consultation: After discussing the oncologist’s clinical needs and reviewing current veterinary lymphoma literature, we recommend a 12-gene panel including:

  • Prognostic markers: BCL2, MYC, TP53
  • Proliferation: KI67, CCND1
  • Apoptosis pathway: BCL2L1, BAX
  • Cell cycle: TP53, CDKN1A
  • B-cell markers: CD20, CD79A
  • Reference genes: RPL13A, ACTB

Pricing: $1,200 one-time setup fee covers design, validation, and acquisition of all primer sets for the 12-gene panel. This is essentially our cost to obtain and validate the primers—it’s a one-time investment, not a per-case charge. Once established, the panel costs just $400 per case thereafter (covering sample processing, reagents, analysis, and consultation).

Long-term value: After just 4-5 cases, the per-case cost drops to $480 total ($1,200 ÷ 4 = $300 amortized setup + $400 per-case). The primer sets can be used for hundreds of samples over time, making this extremely cost-effective for practices that see lymphoma regularly.

Outcome: The oncologist now routinely submits lymph node FNA samples at diagnosis. Cases with high-risk gene expression profiles (high BCL2/MYC, low TP53) receive more aggressive induction protocols and earlier consideration of rescue therapy, while lower-risk cases follow standard CHOP with confidence. Pet owners appreciate the molecular data supporting treatment recommendations. Over 18 months, the oncologist has run 24 cases on this panel, bringing the effective per-case cost to $450 total—far less than alternative diagnostic approaches and providing actionable prognostic information for every case.

Pre-Designed Panels Available

While we specialize in custom design, we’ve also developed several pre-designed panels for common canine cancers based on published literature:

Canine Lymphoma Prognostic Panel (15 genes): BCL2, MYC, TP53, KI67, CCND1, and other validated prognostic markers

Osteosarcoma Metastatic Risk Panel (12 genes): Ezrin, ANKRD17, MGST1, NCOR1, and metastasis-associated genes

Mast Cell Tumor Behavior Panel (10 genes): KIT, TP53, VEGF, tryptase, and markers predicting aggressive behavior

Mammary Carcinoma Receptor Panel (8 genes): ESR1, PGR, HER2, Ki67, and prognostic stromal markers

Contact us for complete gene lists, literature references, and pricing for pre-designed panels.

Practical Considerations for Veterinary Practice

When to Order Gene Expression Analysis

At Initial Diagnosis:

  • To stratify prognosis and guide treatment intensity decisions
  • To subtype cancers when histopathology alone is ambiguous
  • To identify treatment-relevant markers (e.g., KIT in MCT, HER2 in mammary carcinoma)
  • When pet owners want maximum prognostic information to inform treatment decisions

During Treatment:

  • To monitor treatment response in measurable disease
  • To detect early recurrence through minimal residual disease markers
  • To assess whether treatment resistance might be developing

At Relapse:

  • To identify molecular changes that might guide second-line therapy selection
  • To understand mechanisms of treatment failure

Discussing Results with Pet Owners

Gene expression results provide objective, quantitative data that can strengthen conversations with pet owners:

Prognostic Discussions: “The gene expression analysis shows that Max’s lymphoma has a high-risk molecular profile, with significant overexpression of genes associated with treatment resistance. This suggests we should consider a more intensive chemotherapy protocol from the start, rather than starting with standard CHOP and seeing how he does.”

Treatment Decisions: “Bella’s mast cell tumor shows high expression of KIT, which means it’s more likely to respond to targeted therapy with toceranib. Even though the grade was only 2, the molecular profile suggests we should be more aggressive with treatment.”

Realistic Expectations: “The osteosarcoma gene expression panel shows that Duke has several markers associated with high metastatic potential. This doesn’t mean we can’t treat him, but I want you to understand that even with aggressive therapy, his prognosis is more guarded than average. We might want to consider clinical trials of new therapies alongside standard treatment.”

Monitoring: “We’ll repeat the gene expression analysis at the 3-month recheck. If the markers are coming down, we’ll know the treatment is working at the molecular level, even before we see changes on imaging.”

Billing and Practice Integration

Most veterinary practices mark up diagnostic tests 20-30% above cost as part of standard practice management. For example:

  • Custom gene panel-up to 96 genes: $1,200 (your cost, a one-time setup cost and materials acquisition) → Bill client $1,500-1,560
  • Pre-designed panel: $500 (your cost) → Bill client $625-650
  • Additional samples: $400 (your cost, bulk discounts available) → Bill client $500-520

This markup covers your time in case management, sample collection, client communication, and practice overhead while remaining affordable for pet owners compared to the overall cost of cancer treatment.

Insurance Coverage: Many pet insurance policies cover diagnostic testing including advanced molecular diagnostics. We provide detailed invoices itemizing services that pet owners can submit for reimbursement.

Payment Options: We bill veterinary practices directly with NET 30 terms for established accounts, or we can provide quotes for pet owners who prefer to pay directly and seek insurance reimbursement.

Sample Submission Logistics

We make sample submission as straightforward as possible:

Shipping:

  • Prepaid FedEx shipping labels provided upon request
  • FFPE tissue ships at room temperature (no special handling)
  • Fresh frozen tissue ships on dry ice (we provide dry ice sourcing guidance)
  • Typical transit time: 1-2 days within continental US

Turnaround:

  • Standard turnaround: 5-7 business days from sample receipt to results delivery
  • Expedited service available for urgent cases (2-3 day turnaround, additional fee)
  • You receive email notification at each step: sample received, RNA QC complete, analysis in progress, results ready

Communication:

  • Direct phone and email access to our PhD scientists
  • We’ll contact you immediately if sample quality issues arise
  • You’re welcome to call anytime to discuss cases or results

Research Applications and Publication Support

Beyond clinical diagnostics, many veterinary professionals are involved in comparative oncology research, clinical trials, or case series that lead to publication. Our gene expression services support these academic pursuits.

Supporting Veterinary Oncology Research

Clinical Trials: If you’re participating in canine cancer clinical trials, gene expression profiling can provide valuable biomarker data for patient stratification, response assessment, and mechanistic understanding.

Case Series and Retrospective Studies: Access to banked FFPE tissue from previous cases allows retrospective molecular profiling that can generate publishable data on prognostic markers, treatment response correlations, or novel biomarker discovery.

Translational Research: Dogs with naturally occurring cancers are increasingly recognized as valuable models for human cancer. Gene expression data from canine cases contributes to comparative oncology understanding and may support translational research grant applications.

Publication-Quality Data and Support

When your work leads to publication, we provide:

  • Complete materials and methods sections describing qPCR protocols
  • High-resolution publication-quality figures
  • Statistical analysis with appropriate tests and P-values
  • Raw data for supplementary materials if required by journals
  • Co-authorship consideration for substantial intellectual contributions to study design and interpretation (per ICMJE guidelines)

Several veterinary oncology publications have already included data generated through our services, and we’re proud to support the advancement of veterinary cancer research.

Getting Started: Three Easy Paths

Whether you’re a veterinary oncologist managing complex cases or a general practitioner who occasionally encounters cancer patients, we make it easy to begin using gene expression profiling in your practice.

Path 1: Schedule a Free Consultation

Best for: Veterinarians new to molecular diagnostics who want to discuss whether gene expression profiling is right for their practice

What happens:

  • 30-minute phone consultation with our PhD scientists
  • We’ll discuss your typical caseload and clinical questions
  • Review relevant veterinary literature together
  • Provide recommendations on which cancers and genes are most applicable
  • Answer all your questions about sample types, turnaround, pricing
  • No obligation—just education and exploration

Schedule: Call 512.308.1511 or email info@arqgenetics.com with “Veterinary Consultation” in the subject line

Path 2: Submit a Case

Best for: Veterinarians with a current case where gene expression data would be valuable

What happens:

  • Brief discussion of your case and clinical questions
  • We recommend appropriate genes or panel
  • Provide sample submission instructions
  • You send us FFPE slides, fresh tissue, or RNA
  • We handle everything and deliver results with interpretation in 5-7 days

Start: Email info@arqgenetics.com with case details or call 512.308.1511

Path 3: Request Information Packet

Best for: Veterinarians who want written materials to review before engaging

What you receive:

  • Detailed information on our veterinary qPCR services
  • Sample submission guide with instructions and forms
  • Gene lists for pre-designed canine cancer panels
  • Literature references supporting gene selection
  • Pricing information
  • Example reports (de-identified)

Request: Email info@arqgenetics.com with “Veterinary Information Packet” in the subject line, or download materials from our website

The Future of Canine Cancer Diagnostics

Veterinary oncology is rapidly adopting the same molecular approaches that have revolutionized human cancer care. Gene expression profiling, once confined to research laboratories, is becoming a practical clinical tool that helps veterinarians provide more precise diagnoses, more accurate prognoses, and more personalized treatment recommendations.

As our understanding of canine cancer biology deepens through ongoing research, and as more veterinary professionals integrate molecular diagnostics into their practice, we’ll see continued improvements in outcomes for dogs with cancer. Gene expression profiling isn’t replacing traditional diagnostics—it’s enhancing them, providing an additional layer of molecular insight that complements histopathology, imaging, and clinical assessment.

At ARQ Genetics, we’re committed to making this technology accessible, affordable, and clinically relevant for veterinary professionals. Our PhD-level expertise, developed through years of gene expression work with academic researchers, now serves veterinarians who want the same scientific rigor applied to their canine cancer cases—without the regulatory overhead, excessive costs, and long turnaround times that burden human diagnostic testing.

Whether you’re managing a dog with lymphoma and want better prognostic information, treating an osteosarcoma and need to assess metastatic risk, or working with a mast cell tumor and want to know if targeted therapy is appropriate, gene expression profiling provides objective, quantitative data that supports better clinical decisions and more informed conversations with pet owners.

Contact ARQ Genetics for Veterinary Oncology Services

We’re here to support veterinary professionals with expert gene expression analysis for canine cancer cases.

Phone: 512.308.1511
Email: info@arqgenetics.com
Website: www.arqgenetics.com

Services for Veterinarians:

  • Custom canine cancer gene panel design
  • Pre-designed panels for common cancers (lymphoma, osteosarcoma, MCT, mammary carcinoma)
  • Expert consultation with PhD scientists
  • Fast turnaround (5-7 business days standard)
  • Transparent pricing with no hidden fees
  • No minimum case requirements
  • Sample types: FFPE tissue, fresh frozen, FNA, RNA
  • Publication support for research cases

Why Veterinarians Choose ARQ Genetics:

  • PhD-level scientists with years of gene expression expertise
  • Direct consultation and interpretation support included
  • No CLIA/GLP overhead = lower costs, faster turnaround
  • Custom panel design for YOUR specific cases
  • Serving veterinary professionals nationwide

Ready to enhance your canine cancer diagnostics with gene expression profiling? Contact us today to discuss your cases or schedule a free consultation.

References and Further Reading

  1. Klopfleisch R, et al. Tumor-associated stroma in canine mammary carcinomas. Vet Pathol. 2011;48(2):340-351.
  2. Selvarajah GT, et al. Gene expression profiling of canine osteosarcoma reveals genes associated with short and long survival times. Mol Cancer. 2009;8:72.
  3. Gelaleti GB, et al. HYAL-1 expression in canine mammary gland carcinomas: Correlation with tumor grade and clinical outcome. Vet Comp Oncol. 2018;16(4):E181-E188.
  4. Etschmann B, et al. Selection of reference genes for quantitative real-time PCR analysis in canine mammary tumors using the GeNorm algorithm. Vet Pathol. 2006;43(6):934-942.
  5. Lee SH, et al. Molecular expression profile for canine mammary tumors using high-throughput qPCR platform. J Prev Vet Med. 2022;46(1):1-12.
  6. London CA, et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent mast cell tumors. Clin Cancer Res. 2009;15(11):3856-3865.
  7. Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer. 2008;8(2):147-156.
  8. Khanna C, et al. The dog as a cancer model. Nat Biotechnol. 2006;24(9):1065-1066.

This guide was prepared by the PhD scientists at ARQ Genetics to support veterinary professionals in understanding and implementing gene expression profiling for canine cancer diagnostics. For questions, case discussions, or to begin using our services, contact us at info@arqgenetics.com or 512.308.1511.